Viale, Pierluigi
Sandrock, Christian E.
Ramirez, Paula
Rossolini, Gian Maria
Lodise, Thomas P.
Funding for this research was provided by:
Shionogi
Article History
Received: 28 February 2023
Accepted: 31 May 2023
First Online: 15 June 2023
Declarations
:
: Not applicable.
: Not applicable.
: PLV has no conflict of interest. CES has received consultancy fees from Shionogi, Paratek, Abbvie, Pfizer. He is on the speaker bureau for Shionogi, Abbvie, Paratek, Merck. He has been involved in clinical trials from Pleurostem, Jansen, Pfizer, Merck, and Abbive. PR has no conflict of interest. GMR has received consultancy fees from Menarini, MSD, Pfizer, and Zambon. He has participated in speakers’ bureau for Angelini, Menarini, MSD, Pfizer, and Shionogi. GMR has also received grant support for laboratory work from Angelini, Menarini, MSD, Nordic Pharma, Shionogi, VenatorX, and Zambon, all outside of the submitted work. TPL has received consultancy fees from AbbVie, Cidara, Ferring, Genentech, IPCD, Johnson and Johnson, Melinta, Merck, Paratek, Roche, Shionogi, Spero, and VenatorX. He has received grants or research support from BioFire Diagnostics, Entasis, Merck, and Wockhardt. He has participated in speakers’ bureau for Ferring and Shionogi.